Does vimentin help to delineate the so-called 'basal type breast cancer'?

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Kusinska, Renata U ^a   Kordek, Radzislaw ^a   Pluciennik, Elzbieta ^a   Bednarek, Andrzej K ^a   Piekarski, Janusz H ^a   Potemski, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; P CADHERIN; PROGESTERONE RECEPTOR; VIMENTIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; CANCER STAGING; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL;

BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 69949132602     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-118     Document Type: Article

References (35)

1. The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin and alcohol fixed tumors. N Azumi H Battifora, Am J Clin Pathol 1987 88 286 96 2443000
2. Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. MI Kokkinos R Wafai MK Wong DF Newgreen EW Thompson M Waltham, Cells Tissues Organs 2007 185 191 203 10.1159/000101320 17587825 (Pubitemid 46957486)
3. Transactivation of vimentin by beta-catenin in human breast cancer cells. C Gilles M Polette M Mestdagt B Nawrocki-Raby P Ruggeri P Birembaut JM Foidart, Cancer Res 2003 63 2658 64 12750294
4. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? E Korsching J Packeisen C Liedtke D Hungermann P Wülfing PJ van Diest B Brandt W Boecker H Buerger, J Pathol 2005 206 451 7 10.1002/path.1797 15906273 (Pubitemid 41025348)
5. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. MJ Hendrix EA Seftor RE Seftor KT Trevor, Am J Pathol 1997 150 483 95 9033265
6. Identification of gene expression profiles that predict the aggressive behavior of breast cancer. DA Zajchowski MF Bartholdi Y Gong L Webster HL Liu A Munishkin C Beauheim S Harvey SP Ethier PH Johnson, Cancer Res 2001 61 5168 78 11431356
7. Co-expression of cytokeratins and vimentin intermediate filament proteins in benign and neoplastic breast epithelium. WA Raymond AS-Y Leong, J Pathol 1989 157 299 306 10.1002/path.1711570406 2469782 (Pubitemid 19111232)
8. Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. CL Sommers D Walker-Jones SE Heckford P Worland E Valverius R Clark F McCormick M Stampfer S Abularach EP Gelmann, Cancer Res 1989 49 4258 63 2472876
9. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. W Domagala J Lasota J Bartkowiak K Weber M Osborn, Am J Pathol 1990 136 219 227 2153347
10. Vimentin is preferentially expressed in high grade ductal and medullary, but not in lobular breast carcinomas. W Domagala L Wozniak J Lasota K Weber M Osborn, Am J Pathol 1990 137 1059 1064 2173410
11. Vimentin expression in cervical carcinomas: association with invasive and migratory potential. C Gilles M Polette J Piette AC Delvigne EW Thompson JM Foidart P Birembaut, J Pathol 1996 180 175 80 http://www3.interscience.wiley. com/cgi-bin/fulltext/60502373/PDFSTART 8976877 10.1002/(SICI)1096-9896(199610) 180:2<175::AID-PATH630>3.0.CO;2-G
12. Vimentin expression does not assist in predicting survival in ductal carcinoma of the breast. MK Heatley P Ewings W Odling Smee P Maxwell PG Toner, Pathology 2002 34 230 2 10.1080/00313020220131273 12109782 (Pubitemid 34628182)
13. Molecular portraits of human breast tumours. CM Perou T Sørlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov C Williams SX Zhu PE Lønning AL Børresen-Dale PO Brown D Botstein, Nature 2000 406 747 752 10.1038/35021093 10963602 (Pubitemid 30671230)
14. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. T Sørlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn SS Jeffrey T Thorsen H Quist JC Matese PO Brown D Botstein P Eystein Lønning AL Børresen-Dale, Proc Natl Acad Sci USA 2001 98 10869 74 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
15. Repeated observation of breast tumor subtypes in independent gene expression data sets. T Sorlie R Tibshirani J Parker T Hastie JS Marron A Nobel S Deng H Johnsen R Pesich S Geisler J Demeter CM Perou PE Lønning PO Brown AL Børresen-Dale D Botstein, Proc Natl Acad Sci USA 2003 100 8418 23 10.1073/pnas.0932692100 12829800 (Pubitemid 36842560)
16. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. TO Nielsen FD Hsu K Jensen M Cheang G Karaca Z Hu T Hernandez-Boussard C Livasy D Cowan L Dressler LA Akslen J Ragaz AM Gown CB Gilks M van de Rijn CM Perou, Clin Cancer Res 2004 10 5367 74 10.1158/1078-0432.CCR-04-0220 15328174 (Pubitemid 39100473)
17. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma relation with grade, stage, estrogen receptor and HER2. R Kusinska P Potemski D Jesionek-Kupnicka R Kordek, Pol J Pathol 2005 56 107 110 16334976
18. Expression of luminal and basal cytokeratins in human breast carcinoma. DM Abd El-Rehim SE Pinder CE Paish JA Bell RW Blamey JF Robertson RI Nicholson IO Ellis, J Pathol 2004 203 661 671 10.1002/path.1559 15141381 (Pubitemid 38714103)
19. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. B Kreike M van Kouwenhove H Horlings B Weigelt H Peterse H Bartelink MJ van de Vijver, Breast Cancer Res 2007 9 R65 10.1186/bcr1771 17910759 (Pubitemid 350187481)
20. Are triple-negative tumours and basal-like breast cancer synonymous? EA Rakha DS Tan WD Foulkes IO Ellis A Tutt TO Nielsen JS Reis-Filho, Breast Cancer Res 2007 9 404 10.1186/bcr1827 18279542
21. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. C Sotiriou SY Neo LM McShane EL Korn PM Long A Jazaeri P Martiat SB Fox AL Harris ET Liu, Proc Natl Acad Sci USA 2003 100 10393 10398 10.1073/pnas.1732912100 12917485 (Pubitemid 37071889)
22. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. M van de Rijn CM Perou R Tibshirani P Haas O Kallioniemi J Kononen J Torhorst G Sauter M Zuber OR Köchli F Mross H Dieterich R Seitz D Ross D Botstein P Brown, Am J Pathol 2002 161 1991 6 12466114
23. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. M Laakso N Loman A Borg J Isola, Mod Pathol 2005 18 1321 8 10.1038/modpathol.3800456 15990899 (Pubitemid 41348650)
24. Basal and luminal breast cancer: basic or luminous? D Birnbaum F Bertucci C Ginestier R Tagett J Jacquiemier E Charafe-Jauffret, Int J Oncol 2004 25 249 258 15254720
25. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. MC Cheang D Voduc C Bajdik S Leung S McKinney SK Chia CM Perou TO Nielsen, Clin Cancer Res 2008 14 1368 76 10.1158/1078-0432.CCR-07-1658 18316557
26. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. KS McCarty Jr LS Miller EB Cox J Konrath KS McCarty Sr, Arch Pathol Lab Med 1985 109 716 21 3893381
27. Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplasitc and neoplastic breast. VE Gould GK Koukoulis DS Jansson RB Nagle WW Franke R Moll, Am J Pathol 1990 137 1143 1155 1700618
28. Vimentin expression in benign and malignant breast epithelium. M Heatley C Whiteside P Maxwell P Toner, J Clin Pathol 1993 46 441 445 10.1136/jcp.46.5.441 7686566
29. Vimentin expression is not associated with poor prognosis in breast cancer. R Seshadri WA Raymond AS Leong DJ Horsfall K McCaul, Int J Cancer 1996 67 353 6 10.1002/(SICI)1097-0215(19960729)67:3<353::AID-IJC8>3.0.CO;2-Q 8707408
30. Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters. MH Chen GW Yip GM Tse T Moriya PC Lui ML Zin BH Bay PH Tan, Mod Pathol 2008 21 1183 91 10.1038/modpathol.2008.90 18536655
31. Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype. ZB Liu J Wu B Ping LQ Feng JS Lu KW Shen ZZ Shen ZM Shaol, Tumori 2009 95 53 62 19366057
32. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. EA Rakha SE Elsheikh MA Aleskandarany HO Habashi AR Green DG Powe ME El-Sayed A Benhasouna JS Brunet LA Akslen AJ Evans R Blamey JS Reis-Filho WD Foulkes IO Ellis, Clin Cancer Res 2009 15 2302 10 10.1158/1078-0432.CCR-08-2132 19318481
33. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. M Jumppanen S Gruvberger-Saal P Kauraniemi M Tanner PO Bendahl M Lundin M Krogh P Kataja A Borg M Fernö J Isola, Breast Cancer Res 2007 9 R16 10.1186/bcr1649 17263897 (Pubitemid 350215145)
34. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. M Tischkowitz JS Brunet LR Bégin DG Huntsman MC Cheang LA Akslen TO Nielsen WD Foulkes, BMC Cancer 2007 7 134 10.1186/1471-2407-7-134 17650314 (Pubitemid 47272190)
35. Prognostic relevance of basal cytokeratins expression in operable breast cancer. P Potemski R Kusinska C Watala E Pluciennik AK Bednarek R Kordek, Oncology 2005 69 478 485 10.1159/000090986 16410686